<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 4, 2026 at 4:29 PM by All in One SEO v5.0.4 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Wed, 04 Nov 2026 05:27:30 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/paq-therapeutics-to-present-first-pt0253-clinical-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/paq-therapeutics-to-present-first-pt0253-clinical-data/]]></link>
			<title>PAQ Therapeutics to Present First PT0253 Clinical Data</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 05:27:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/safi-wins-4-7m-to-advance-manufactured-red-blood-cell-trials/]]></guid>
			<link><![CDATA[https://cgxpwire.com/safi-wins-4-7m-to-advance-manufactured-red-blood-cell-trials/]]></link>
			<title>Safi Wins $4.7M to Advance Manufactured Red Blood Cell Trials</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 05:18:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/allergan-aesthetics-shares-new-research-at-asds-2026-meeting/]]></guid>
			<link><![CDATA[https://cgxpwire.com/allergan-aesthetics-shares-new-research-at-asds-2026-meeting/]]></link>
			<title>Allergan Aesthetics Shares New Research at ASDS 2026 Meeting</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 05:13:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/thryv-raises-30m-to-advance-thrv-1268-heart-studies/]]></guid>
			<link><![CDATA[https://cgxpwire.com/thryv-raises-30m-to-advance-thrv-1268-heart-studies/]]></link>
			<title>Thryv Raises $30M to Advance THRV-1268 Heart Studies</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 05:10:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cstone-and-kimia-partner-to-advance-novel-cancer-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cstone-and-kimia-partner-to-advance-novel-cancer-drug/]]></link>
			<title>CStone and Kimia Partner to Advance Novel Cancer Drug</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 05:06:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cepheid-wins-fda-clearance-for-hemorrhagic-fever-panel/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cepheid-wins-fda-clearance-for-hemorrhagic-fever-panel/]]></link>
			<title>Cepheid Wins FDA Clearance for Hemorrhagic Fever Panel</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:48:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medtronic-reports-positive-spyral-affirm-blood-pressure-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medtronic-reports-positive-spyral-affirm-blood-pressure-results/]]></link>
			<title>Medtronic Reports Positive SPYRAL AFFIRM Blood Pressure Results</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:47:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lupin-launches-raltegravir-600-mg-tablets-in-the-u-s-market/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lupin-launches-raltegravir-600-mg-tablets-in-the-u-s-market/]]></link>
			<title>Lupin Launches Raltegravir 600 mg Tablets in the U.S. Market</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:42:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/aeye-health-wins-2026-prix-galien-award-for-ai-eye-screening/]]></guid>
			<link><![CDATA[https://cgxpwire.com/aeye-health-wins-2026-prix-galien-award-for-ai-eye-screening/]]></link>
			<title>AEYE Health Wins 2026 Prix Galien Award for AI Eye Screening</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:39:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/beckman-coulter-wins-fda-clearance-for-rapid-infection-test/]]></guid>
			<link><![CDATA[https://cgxpwire.com/beckman-coulter-wins-fda-clearance-for-rapid-infection-test/]]></link>
			<title>Beckman Coulter Wins FDA Clearance for Rapid Infection Test</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:37:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/graviton-bioscience-wins-fda-fast-track-for-gv101-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/graviton-bioscience-wins-fda-fast-track-for-gv101-therapy/]]></link>
			<title>Graviton BioScience Wins FDA Fast Track for GV101 Therapy</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:21:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/bridge-to-life-wins-canada-license-fda-breakthrough-status/]]></guid>
			<link><![CDATA[https://cgxpwire.com/bridge-to-life-wins-canada-license-fda-breakthrough-status/]]></link>
			<title>Bridge to Life Wins Canada License, FDA Breakthrough Status</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:18:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lupin-secures-u-s-fda-approval-for-amifampridine-10-mg/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lupin-secures-u-s-fda-approval-for-amifampridine-10-mg/]]></link>
			<title>Lupin Secures U.S. FDA Approval for Amifampridine 10 mg</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 04:11:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/roche-wins-fda-clearance-for-cobas-eplex-rp3-panel/]]></guid>
			<link><![CDATA[https://cgxpwire.com/roche-wins-fda-clearance-for-cobas-eplex-rp3-panel/]]></link>
			<title>Roche Wins FDA Clearance for cobas eplex RP3 Panel</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 03:58:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/contrario-medical-wins-fda-clearance-for-cyperus-device/]]></guid>
			<link><![CDATA[https://cgxpwire.com/contrario-medical-wins-fda-clearance-for-cyperus-device/]]></link>
			<title>Contrario Medical Wins FDA Clearance for Cyperus Device</title>
			<pubDate><![CDATA[Wed, 04 Nov 2026 03:55:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/neurocrine-launches-cah-education-tools-for-healthcare-teams/]]></guid>
			<link><![CDATA[https://cgxpwire.com/neurocrine-launches-cah-education-tools-for-healthcare-teams/]]></link>
			<title>Neurocrine Launches CAH Education Tools for Healthcare Teams</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 05:09:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/inovio-wins-fda-approval-for-voceryq-in-rrp-treatment/]]></guid>
			<link><![CDATA[https://cgxpwire.com/inovio-wins-fda-approval-for-voceryq-in-rrp-treatment/]]></link>
			<title>INOVIO Wins FDA Approval for VOCERYQ in RRP Treatment</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 05:05:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/flagship-launches-etcelera-to-transform-ai-drug-discovery/]]></guid>
			<link><![CDATA[https://cgxpwire.com/flagship-launches-etcelera-to-transform-ai-drug-discovery/]]></link>
			<title>Flagship Launches Etcelera to Transform AI Drug Discovery</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 05:01:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/eloxx-wins-fda-ind-clearance-for-exaluren-in-adpkd/]]></guid>
			<link><![CDATA[https://cgxpwire.com/eloxx-wins-fda-ind-clearance-for-exaluren-in-adpkd/]]></link>
			<title>Eloxx Wins FDA IND Clearance for Exaluren in ADPKD</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:56:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/adc-therapeutics-advances-zynlonta-japan-approval-filing/]]></guid>
			<link><![CDATA[https://cgxpwire.com/adc-therapeutics-advances-zynlonta-japan-approval-filing/]]></link>
			<title>ADC Therapeutics Advances ZYNLONTA Japan Approval Filing</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:47:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/nuvation-bio-expands-phase-3-safusidenib-trial-across-europe/]]></guid>
			<link><![CDATA[https://cgxpwire.com/nuvation-bio-expands-phase-3-safusidenib-trial-across-europe/]]></link>
			<title>Nuvation Bio Expands Phase 3 Safusidenib Trial Across Europe</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:43:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/altruist-biologics-advances-nmpa-review-for-localized-production/]]></guid>
			<link><![CDATA[https://cgxpwire.com/altruist-biologics-advances-nmpa-review-for-localized-production/]]></link>
			<title>Altruist Biologics Advances NMPA Review for Localized Production</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:39:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/sun-pharma-wins-fda-approval-for-ilumya-in-psoriatic-arthritis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/sun-pharma-wins-fda-approval-for-ilumya-in-psoriatic-arthritis/]]></link>
			<title>Sun Pharma Wins FDA Approval for ILUMYA in Psoriatic Arthritis</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:30:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/daiichi-sankyo-seeks-eu-approval-for-triple-lipid-therapies/]]></guid>
			<link><![CDATA[https://cgxpwire.com/daiichi-sankyo-seeks-eu-approval-for-triple-lipid-therapies/]]></link>
			<title>Daiichi Sankyo Seeks EU Approval for Triple Lipid Therapies</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:23:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cerevasc-wins-fda-ide-approval-for-alzheimers-eshunt-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cerevasc-wins-fda-ide-approval-for-alzheimers-eshunt-trial/]]></link>
			<title>CereVasc Wins FDA IDE Approval for Alzheimer’s eShunt Trial</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:19:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/asymchem-completes-first-usfda-inspection-at-tianjin-4-site/]]></guid>
			<link><![CDATA[https://cgxpwire.com/asymchem-completes-first-usfda-inspection-at-tianjin-4-site/]]></link>
			<title>Asymchem Completes First USFDA Inspection at Tianjin 4 Site</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:14:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/oncoc4-to-present-new-cesalatamig-data-at-sitc-2026-meeting/]]></guid>
			<link><![CDATA[https://cgxpwire.com/oncoc4-to-present-new-cesalatamig-data-at-sitc-2026-meeting/]]></link>
			<title>OncoC4 to Present New Cesalatamig Data at SITC 2026 Meeting!</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:05:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/novavax-earns-125m-as-sanofi-starts-phase-3-vaccine-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/novavax-earns-125m-as-sanofi-starts-phase-3-vaccine-trial/]]></link>
			<title>Novavax Earns $125M as Sanofi Starts Phase 3 Vaccine Trial</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:04:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/kimberly-clark-completes-kenvue-acquisition-expands-health/]]></guid>
			<link><![CDATA[https://cgxpwire.com/kimberly-clark-completes-kenvue-acquisition-expands-health/]]></link>
			<title>Kimberly-Clark Completes Kenvue Acquisition, Expands Health</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 04:04:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/review-examines-linoleic-acid-rich-oils-and-health-outcomes/]]></guid>
			<link><![CDATA[https://cgxpwire.com/review-examines-linoleic-acid-rich-oils-and-health-outcomes/]]></link>
			<title>Review Examines Linoleic Acid-Rich Oils and Health Outcomes!</title>
			<pubDate><![CDATA[Tue, 03 Nov 2026 03:20:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/u-s-renal-care-presents-eight-kidney-research-studies-at-asn/]]></guid>
			<link><![CDATA[https://cgxpwire.com/u-s-renal-care-presents-eight-kidney-research-studies-at-asn/]]></link>
			<title>U.S. Renal Care Presents Eight Kidney Research Studies at ASN</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:25:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/resonant-launches-sample-asset-management-programs-for-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/resonant-launches-sample-asset-management-programs-for-trial/]]></link>
			<title>Resonant Launches Sample Asset Management Programs for Trial</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:24:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cosara-hpv-test-study-highlights-cervical-cancer-screening/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cosara-hpv-test-study-highlights-cervical-cancer-screening/]]></link>
			<title>CoSara HPV Test Study Highlights Cervical Cancer Screening</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:24:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/novo-nordisk-to-present-26-obesity-data-abstracts-at-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/novo-nordisk-to-present-26-obesity-data-abstracts-at-2026/]]></link>
			<title>Novo Nordisk to Present 26 Obesity Data Abstracts at 2026</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:23:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/instylla-wins-fda-approval-for-embrace-bleeding-device/]]></guid>
			<link><![CDATA[https://cgxpwire.com/instylla-wins-fda-approval-for-embrace-bleeding-device/]]></link>
			<title>Instylla Wins FDA Approval for Embrace Bleeding Device</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:22:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/azitra-expands-atr-04-trial-for-cancer-related-skin-rashes/]]></guid>
			<link><![CDATA[https://cgxpwire.com/azitra-expands-atr-04-trial-for-cancer-related-skin-rashes/]]></link>
			<title>Azitra Expands ATR-04 Trial for Cancer-Related Skin Rashes</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:21:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/abbott-launches-pivotal-trial-of-cephea-mitral-valve/]]></guid>
			<link><![CDATA[https://cgxpwire.com/abbott-launches-pivotal-trial-of-cephea-mitral-valve/]]></link>
			<title>Abbott Launches Pivotal Trial of Cephea Mitral Valve</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:21:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/johnson-johnson-presents-26-impella-studies-at-tct-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/johnson-johnson-presents-26-impella-studies-at-tct-2026/]]></link>
			<title>Johnson &amp; Johnson Presents 26 Impella Studies at TCT 2026!</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:20:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biomarin-licenses-next-gen-fabry-disease-therapy-worldwide/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biomarin-licenses-next-gen-fabry-disease-therapy-worldwide/]]></link>
			<title>BioMarin Licenses Next-Gen Fabry Disease Therapy Worldwide</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:19:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/sobi-reports-positive-phase-3-pozdeutinurad-gout-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/sobi-reports-positive-phase-3-pozdeutinurad-gout-data/]]></link>
			<title>Sobi Reports Positive Phase 3 Pozdeutinurad Gout Data</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:18:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/us-worldmeds-acquires-orbus-to-advance-glioma-drug-research/]]></guid>
			<link><![CDATA[https://cgxpwire.com/us-worldmeds-acquires-orbus-to-advance-glioma-drug-research/]]></link>
			<title>US WorldMeds Acquires Orbus to Advance Glioma Drug Research</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:17:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/eli-lilly-retatrutide-shows-strong-phase-3-diabetes-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/eli-lilly-retatrutide-shows-strong-phase-3-diabetes-results/]]></link>
			<title>Eli Lilly Retatrutide Shows Strong Phase 3 Diabetes Results!</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:16:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/palvella-gains-fda-priority-review-for-qtorin-rapamycin-nda/]]></guid>
			<link><![CDATA[https://cgxpwire.com/palvella-gains-fda-priority-review-for-qtorin-rapamycin-nda/]]></link>
			<title>Palvella Gains FDA Priority Review for QTORIN Rapamycin NDA!</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:16:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/novo-nordisk-to-present-12-new-liver-research-abstracts/]]></guid>
			<link><![CDATA[https://cgxpwire.com/novo-nordisk-to-present-12-new-liver-research-abstracts/]]></link>
			<title>Novo Nordisk to Present 12 New Liver Research Abstracts</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:15:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/hotspot-therapeutics-to-present-hst-2011-autoimmune-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/hotspot-therapeutics-to-present-hst-2011-autoimmune-data/]]></link>
			<title>HotSpot Therapeutics to Present HST-2011 Autoimmune Data</title>
			<pubDate><![CDATA[Mon, 02 Nov 2026 03:14:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/avenzo-to-present-avzo-023-phase-1-results-at-sabcs-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/avenzo-to-present-avzo-023-phase-1-results-at-sabcs-2026/]]></link>
			<title>Avenzo to Present AVZO-023 Phase 1 Results at SABCS 2026</title>
			<pubDate><![CDATA[Sat, 31 Oct 2026 04:58:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/immunome-receives-ema-validation-for-varegacestat-application/]]></guid>
			<link><![CDATA[https://cgxpwire.com/immunome-receives-ema-validation-for-varegacestat-application/]]></link>
			<title>Immunome Receives EMA Validation for Varegacestat Application</title>
			<pubDate><![CDATA[Sat, 31 Oct 2026 04:53:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/propanc-advances-ppc-001-assay-development-for-phase-1b-cancer-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/propanc-advances-ppc-001-assay-development-for-phase-1b-cancer-study/]]></link>
			<title>Propanc Advances PPC-001 Assay Development for Phase 1b Cancer Study</title>
			<pubDate><![CDATA[Sat, 31 Oct 2026 04:48:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/moleculin-completes-miracle-trial-part-a-dosing-in-r-r-aml/]]></guid>
			<link><![CDATA[https://cgxpwire.com/moleculin-completes-miracle-trial-part-a-dosing-in-r-r-aml/]]></link>
			<title>Moleculin Completes MIRACLE Trial Part A Dosing in R/R AML</title>
			<pubDate><![CDATA[Sat, 31 Oct 2026 04:45:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/atsena-reports-promising-atsn-301-preclinical-data-for-usher-1b/]]></guid>
			<link><![CDATA[https://cgxpwire.com/atsena-reports-promising-atsn-301-preclinical-data-for-usher-1b/]]></link>
			<title>Atsena Reports Promising ATSN-301 Preclinical Data for Usher 1B</title>
			<pubDate><![CDATA[Sat, 31 Oct 2026 04:42:31 +0000]]></pubDate>
		</item>
				</channel>
</rss>
